(TFX) Teleflex - Overview
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NYSE (USA) | Market Cap: 5.877m USD | Total Return: 8.5% in 12m
Avg Turnover: 98.9M
EPS Trend: -45.7%
Qual. Beats: 0
Rev. Trend: 10.1%
Qual. Beats: 0
Warnings
Interest Coverage Ratio -2.0 is critical
Choppy
Tailwinds
No distinct edge detected
Teleflex Incorporated (TFX) is a global provider of medical technologies specializing in single-use devices for critical care and surgical applications. Its portfolio includes vascular access systems, interventional cardiology products, and surgical instruments under established brands such as Arrow, QuikClot, and Weck. The company serves a diverse client base ranging from hospitals and healthcare providers to original equipment manufacturers (OEMs).
Operating within the Health Care Equipment sector, Teleflex utilizes a business model heavily weighted toward high-volume, disposable consumables. This strategy reduces exposure to hospital capital expenditure cycles and creates recurring revenue streams linked to procedure volumes. The company maintains a global manufacturing and distribution footprint, supporting clinical needs in emergency medicine, bariatric surgery, and interventional oncology.
For a more granular look at these financial drivers, consider reviewing the detailed metrics available on ValueRay.
- UroLift system procedure volume recovery remains critical for high-margin revenue growth
- MANTA vascular closure device adoption drives interventional segment market share gains
- Hospital budget constraints and elective procedure deferrals impact organic sales growth
- Strategic M&A integration and portfolio optimization influence long-term operating margin expansion
- Global supply chain stability and raw material costs affect manufacturing profitability margins
| Net Income: -1.01b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -3.03 > 1.0 |
| NWC/Revenue: 40.25% < 20% (prev 28.67%; Δ 11.58% < -1%) |
| CFO/TA 0.05 > 3% & CFO 314.2m > Net Income -1.01b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.55 > 1.5 & < 3 |
| Outstanding Shares: last quarter (44.3m) vs 12m ago -3.63% < -2% |
| Gross Margin: 53.27% > 18% (prev 0.56%; Δ 5.27k% > 0.5%) |
| Asset Turnover: 40.31% > 50% (prev 42.02%; Δ -1.71% > 0%) |
| Interest Coverage Ratio: -1.97 > 6 (EBITDA TTM -88.5m / Interest Expense TTM 113.2m) |
| A: 0.17 (Total Current Assets 1.86b - Total Current Liabilities 728.0m) / Total Assets 6.78b |
| B: 0.46 (Retained Earnings 3.13b / Total Assets 6.78b) |
| C: -0.03 (EBIT TTM -222.9m / Avg Total Assets 6.97b) |
| D: 0.85 (Book Value of Equity 3.13b / Total Liabilities 3.70b) |
| Altman-Z'' = 3.27 = A |
| DSRI: 0.84 (Receivables 365.5m/464.5m, Revenue 2.81b/3.01b) |
| GMI: 1.05 (GM 53.27% / 55.68%) |
| AQI: 0.92 (AQ_t 0.64 / AQ_t-1 0.70) |
| SGI: 0.93 (Revenue 2.81b / 3.01b) |
| TATA: -0.20 (NI -1.01b - CFO 314.2m) / TA 6.78b) |
| Beneish M = -3.41 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at USD 131.89 with a total of 784,477 shares traded.
Over the past week, the price has changed by +1.40%,
over one month by -2.10%,
over three months by +11.42% and
over the past year by +8.49%.
Teleflex has received a consensus analysts rating of 3.07. Therefore, it is recommended to hold TFX.
- StrongBuy: 0
- Buy: 2
- Hold: 11
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 143.7 | 8.9% |
P/E Trailing = 1896.4286
P/E Forward = 20.1207
P/S = 2.7634
P/B = 1.9053
P/EG = 0.1641
Revenue TTM = 2.81b USD
EBIT TTM = -222.9m USD
EBITDA TTM = -88.5m USD
Long Term Debt = 2.51b USD (from longTermDebt, last quarter)
Short Term Debt = 103.1m USD (from shortTermDebt, last quarter)
Debt = 2.69b USD (corrected: LT Debt 2.51b + ST Debt 103.1m) + Leases 68.3m
Net Debt = 2.38b USD (calculated: Debt 2.69b - CCE 309.4m)
Enterprise Value = 8.25b USD (5.88b + Debt 2.69b - CCE 309.4m)
Interest Coverage Ratio = -1.97 (Ebit TTM -222.9m / Interest Expense TTM 113.2m)
EV/FCF = 33.14x (Enterprise Value 8.25b / FCF TTM 249.0m)
FCF Yield = 3.02% (FCF TTM 249.0m / Enterprise Value 8.25b)
FCF Margin = 8.86% (FCF TTM 249.0m / Revenue TTM 2.81b)
Net Margin = -35.89% (Net Income TTM -1.01b / Revenue TTM 2.81b)
Gross Margin = 53.27% ((Revenue TTM 2.81b - Cost of Revenue TTM 1.31b) / Revenue TTM)
Gross Margin QoQ = 56.07% (prev 54.03%)
Tobins Q-Ratio = 1.22 (Enterprise Value 8.25b / Total Assets 6.78b)
Interest Expense / Debt = 4.21% (Interest Expense 113.2m / Debt 2.69b)
Taxrate = 21.0% (US default 21%)
NOPAT = -176.1m (EBIT -222.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.55 (Total Current Assets 1.86b / Total Current Liabilities 728.0m)
Debt / Equity = 0.87 (Debt 2.69b / totalStockholderEquity, last quarter 3.08b)
Debt / EBITDA = -26.86 (negative EBITDA) (Net Debt 2.38b / EBITDA -88.5m)
Debt / FCF = 9.54 (Net Debt 2.38b / FCF TTM 249.0m)
Total Stockholder Equity = 3.57b (last 4 quarters mean from totalStockholderEquity)
RoA = -14.47% (Net Income -1.01b / Total Assets 6.78b)
RoE = -28.27% (Net Income TTM -1.01b / Total Stockholder Equity 3.57b)
RoCE = -3.66% (EBIT -222.9m / Capital Employed (Equity 3.57b + L.T.Debt 2.51b))
RoIC = -2.88% (negative operating profit) (NOPAT -176.1m / Invested Capital 6.12b)
WACC = 6.79% (E(5.88b)/V(8.56b) * Re(8.37%) + D(2.69b)/V(8.56b) * Rd(4.21%) * (1-Tc(0.21)))
Discount Rate = 8.37% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -76.41 | Cagr: -2.91%
[DCF] Terminal Value 73.10% ; FCFF base≈341.3m ; Y1≈299.3m ; Y5≈241.9m
[DCF] Fair Price = 34.01 (EV 3.88b - Net Debt 2.38b = Equity 1.51b / Shares 44.3m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -45.70 | EPS CAGR: -3.87% | SUE: 0.25 | # QB: 0
Revenue Correlation: 10.09 | Revenue CAGR: 0.34% | SUE: 0.02 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.27 | Chg30d=-7.77% | Revisions=-14% | Analysts=11
EPS next Quarter (2026-09-30): EPS=1.82 | Chg30d=-8.59% | Revisions=-43% | Analysts=11
EPS current Year (2026-12-31): EPS=6.70 | Chg30d=-0.31% | Revisions=+38% | GrowthEPS=-4.0% | GrowthRev=+15.3%
EPS next Year (2027-12-31): EPS=10.46 | Chg30d=+0.94% | Revisions=+23% | GrowthEPS=+56.2% | GrowthRev=+4.9%
[Analyst] Revisions Ratio: -43%